CUE-101with Pembrolizumab for LA-HPV+HNSCCs

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A\*0201-positive treatment naive participants with locally advanced, unresectable HPV-16 associated head and neck squamous cell carcinoma (HNSCC).
Epistemonikos ID: 150b75efd540f28c5bf10a7fa93cc55073032a97
First added on: Sep 16, 2025